Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.50 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.47 |
| ▸ | IAPP | P10997 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NQO2 | P16083 | 1/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | ACP3 | P15309 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30258002 | 0.90 | IAPP (0.56) | MTNR1ACDYLTDP1GPR84IAPP | |
| SCHEMBL4070601 | 0.90 | IAPP (0.56) | MTNR1ACDYLTDP1GPR84IAPP | |
| SCHEMBL7340131 | 0.90 | TDP1 (0.58) | MTNR1ACDYLTDP1GPR84IAPP | |
| SCHEMBL8400463 | 0.83 | IAPP (0.58) | MTNR1ACDYLTDP1GPR84IAPP | |
| SCHEMBL9404001 | 0.83 | MTNR1A (0.58) | MTNR1ACDYLTDP1GPR84KDM4E | |
| SCHEMBL6708222 | 0.82 | MTNR1A (0.50) | MTNR1ACDYLTDP1GPR84IAPP | |
| SCHEMBL13227199 | 0.81 | CDYL (0.53) | MTNR1ACDYLTDP1GPR84IAPP | |
| SCHEMBL27891939 | 0.80 | TDP1 (0.51) | MTNR1ACDYLTDP1GPR84KDM4E | |
| SCHEMBL14608998 | 0.79 | MTNR1A (0.49) | MTNR1ACDYLTDP1GPR84IAPP | |
| SCHEMBL29137509 | 0.79 | ACP3 (0.52) | MTNR1ACDYLTDP1GPR84KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6911468-B2 | Tyrosine phosphatase inhibitors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-06-28 | — | — | US | disclosed |
| US-20030144338-A1 | Tyrosine phosphatase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-07-31 | — | — | US | disclosed |
| EP-1284260-A1 | TYROSINE PHOSPHATASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2003-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144338-A1 | Tyrosine phosphatase inhibitors | PTPRC, PTPN1, PTPRM | MTNR1A 673/4885CDYL 174/4885TDP1 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.